submit to the journals

Alzheimer's Disease & Dementia Journal Articles, Videos And Insights

Alzheimer's Disease & Dementia: FEATURED Articles

flipper_slider

Alzheimer's Disease & Dementia: FEATURED VIDEOS

Editor's choice

Jeffrey L Cummings (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV), a valued member of our editorial board for US Neurology, discusses how disease-modification is being approached for Alzheimer's disease and the important emerging role of monoclonal antibodies, which are being used to target various biological targets in Alzheimer's in clinical trials. Questions 1. How is disease-modification being approached for Alzheimer’s disease (AD)? (0:12) 2. What role do monocloncal antibodies have in the treatment of AD? (0:43) 3. When in the course of AD should monocloncal antibodies be used? (1:32) 4. What are the biological targets of monocloncal antibodies? (2:47) 5. What are some of the promising monocloncal antibodies in trials now? (3:30) 6. What are the major challenges to developing monocloncal antibodies? (4:19) Speaker disclosure: Jeffrey L Cummings has provided consultation to the following pharmaceutical companies: Acadia, Accera, Actinogen, ADAMAS, Alkahest, Allergan, Alzheon, Avanir, Axovant, Axsome, BiOasis Technologies, Biogen, Eisai, Genentech, Grifols, Kyowa, Lilly, Lundbeck, Merck, Nutricia, Otsuka, QR Pharma, Resverlogix, Roche, Samus, Servier, Suven, Takeda, Toyoma, and United Neuroscience companies. Dr Cummings has provided consultation to Neurocog, MedAvante, and Bracket assessment companies, as well as the Global Alzheimer Platform (GAP) foundation. Dr Cummings owns stocks in Cummings owns stocks in ADAMAS, Alzheon, BioAsis, EIP Pharma, Prana, Sonexa, MedAvante, Neurotrax, and QR Pharma. Dr Cummings owns the copyright of the Neuropsychiatric Inventory, and receives research support from Avid and Teva. NIH support: COBRE grant# P20GM109025; TRC-PAD # R01AG053798; DIAGNOSE CTE # U01NS093334. Filmed during a video call with Jeffrey L Cummings from his office at the Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, US, May 2018.
Philip Scheltens (EAN Programme Committee; Professor of Cognitive Neurology and Director, Alzheimer Center, VU Medical Center, Amsterdam, The Netherlands) speaks to us following his Edouard Brown-Séquard Lecture during the Presidential Symposium entitled: The evolution of Alzheimer’s disease and dementia. Questions 1. How have diagnostic criteria evolved in Alzheimer’s disease (AD)? (0:12) 2. What progress has been made in research to identify biomarkers in AD? (0:41) 3. What is your opinion on the concept of mild cognitive impairment to detect early AD? (1:16) 4. Why have so many clinical trials for AD failed? (1:50) 5. What new treatment modalities do you expect to emerge in the coming year? (2:32) Speaker disclosure: Philip Scheltens has nothing to disclose in relation to this video interview. Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.

Alzheimer's Disease & Dementia: Latest Videos

Video List based on Category on Node Page

Latest Videos

Philip Scheltens (EAN Programme Committee; Professor of Cognitive Neurology and Director, Alzheimer Center, VU Medical Center, Amsterdam, The Netherlands) speaks to us following his Edouard Brown-Séquard Lecture during the Presidential Symposium entitled: The evolution of Alzheimer’s disease...
Jeffrey L Cummings (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV), a valued member of our editorial board for US Neurology, discusses how disease-modification is being approached for Alzheimer's disease and the important emerging role of monoclonal antibodies, which are being...
Video of care home dementia champions speaking emotionally about the impact of the Improving Wellbeing and Health for People with Dementia (WHELD) training programme. This project was funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research...
Sean Knox talks to us about the aims of the Innovative Medicines Initiative – European Prevention of Alzheimer’s Dementia Consortium (IMI-EPAD), progress to date and where further information can be found on this important project. Visit EPAD here. Speaker disclosures: Full time employee of...
Prof. Martin Farlow, esteemed member of the US Neurology Editorial Board, discusses the use of antipsychotics in adults with dementia, and the benefit of tau imaging in the diagnosis of Alzheimers. Part 2 of 2. View part 1 here. Filmed at the American Academy of Neurology (AAN) Annual Meeting,...
Prof. Martin Farlow, esteemed member of the US Neurology Editorial Board, discusses the recent clinical trial of solanezumab in Alzheimer's disease and the current treatment landscape. Part 1 of 2. View part 2 here. Filmed at the American Academy of Neurology (AAN) Annual Meeting, Boston, US,...

LATEST TWEETS

Conference Highlights